Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01PLR
|
|||
| Former ID |
DNCL001671
|
|||
| Drug Name |
PF-04171327
|
|||
| Synonyms |
Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; PF-04171327; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Pfizer New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H30F3N2O5P
|
|||
| Canonical SMILES |
CC1=C(C=CC=N1)NC(=O)C2=CC3=C(C=C2)C4(CCC(CC4CC3)(C(F)(F)F)OP(=O)(O)O)CC5=CC=CC=C5
|
|||
| InChI |
1S/C29H30F3N2O5P/c1-19-25(8-5-15-33-19)34-26(35)22-10-12-24-21(16-22)9-11-23-18-28(29(30,31)32,39-40(36,37)38)14-13-27(23,24)17-20-6-3-2-4-7-20/h2-8,10,12,15-16,23H,9,11,13-14,17-18H2,1H3,(H,34,35)(H2,36,37,38)/t23-,27+,28-/m1/s1
|
|||
| InChIKey |
BVXLAHSJXXSWFF-KEKPKEOLSA-N
|
|||
| CAS Number |
CAS 1044535-58-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00938587) A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.